InvestorsHub Logo
Followers 4
Posts 207
Boards Moderated 0
Alias Born 03/06/2022

Re: frrol post# 458807

Saturday, 05/11/2024 1:50:36 PM

Saturday, May 11, 2024 1:50:36 PM

Post# of 459708
frrol, I might add that the path to approval has likely also been helped by the mixed reception of the three recent mAb treatments at the FDA and EMA, and by lackluster uptake of Leqembi specifically in the marketplace.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News